Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | TYMS | P04818 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13966269 | 0.89 | MAPT (0.46) | ATMMAPTTSHRL3MBTL1PARP1 | |
| SCHEMBL13976027 | 0.83 | CYP1A2 (0.46) | MAPTPARP1ALDH1A1ESR1MAPK1 | |
| SCHEMBL13966259 | 0.79 | ATM (0.56) | ATMMAPTTSHRL3MBTL1BTK | |
| SCHEMBL13975114 | 0.76 | POLB (0.46) | ATMMAPTL3MBTL1ALDH1A1MAPK1 | |
| SCHEMBL13966261 | 0.75 | MAPT (0.47) | ATMMAPTTSHRL3MBTL1BTK | |
| SCHEMBL13966260 | 0.73 | HTR4 (0.47) | ATMMAPTTSHRL3MBTL1PARP1 | |
| SCHEMBL13966264 | 0.72 | MAPT (0.47) | ATMMAPTTSHRL3MBTL1BTK | |
| SCHEMBL28084002 | 0.70 | CYP1A2 (0.46) | MAPTTSHRPARP1ALDH1A1KDM4E | |
| SCHEMBL13409375 | 0.70 | ALOX5AP (0.40) | ATMMAPTTSHRL3MBTL1ALDH1A1 | |
| SCHEMBL13966274 | 0.70 | MAPT (0.48) | ATMMAPTTSHRL3MBTL1BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8951964-B2 | Phenanthridine macrocyclic hepatitis C serine protease inhibitors | ABBVIE INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20120295842-A1 | PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ABBVIE INC. | 2012-11-22 | — | — | US | disclosed |
| US-20120295842-A1 | PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ABBVIE INC. | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295842-A1 | PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS15, HPN, PRSS1 | ATM 4349/4885MAPT 3503/4885TSHR 3946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.